UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 97

Sortiert nach

The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials

Annals of oncology, 2010-10, Vol.21 (10), p.2023-2028

2010

Volltextzugriff (PDF)

Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients

Quality of life research, 2015-03, Vol.24 (3), p.591-598

2015

Volltextzugriff (PDF)

Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting

Current oncology (Toronto), 2012-12, Vol.19 (6), p.e414-421

2012

Volltextzugriff (PDF)

Consolidative durvalumab outcomes in stage III non-small cell lung cancer in a multi-centre study

Cancer treatment and research communications, 2021, Vol.29, p.100496-100496, Article 100496

2021

Volltextzugriff (PDF)

The role of palliative chemotherapy in hospitalized patients

Current oncology (Toronto), 2014-08, Vol.21 (4), p.187-192

2014

Volltextzugriff (PDF)

The most important attribute: stakeholder perspectives on what matters most in a physician

Current oncology (Toronto), 2020-04, Vol.27 (2), p.100-106

2020

Volltextzugriff (PDF)

Chemotherapy in recurrent advanced non-small-cell lung cancer after adjuvant chemotherapy

Current oncology (Toronto), 2016-12, Vol.23 (6), p.386-390

2016

Volltextzugriff (PDF)

Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients?

Current oncology (Toronto), 2018-08, Vol.25 (4), p.e291-297

2018

Volltextzugriff (PDF)

Palliative chemotherapy in advanced colorectal cancer patients 80 years of age and older

Current oncology (Toronto), 2016-06, Vol.23 (3), p.144-153

2016

Volltextzugriff (PDF)

Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 patient-reported outcomes (PROs)

Annals of oncology, 2018-10, Vol.29, p.viii91-viii91

2018

Volltextzugriff (PDF)

Analyzing the effect of physician assignment in the survival of patients with advanced non-small-cell lung cancer

Current oncology (Toronto), 2020-02, Vol.27 (1), p.34-38

2020

Volltextzugriff (PDF)

Non-bacterial thrombotic endocarditis during treatment for EGFR mutation positive lung cancer

Current problems in cancer. Case reports, 2022-03, Vol.5, p.100148, Article 100148

2022

Volltextzugriff (PDF)

Standardizing biomarker testing for Canadian patients with advanced lung cancer

Current oncology (Toronto), 2018-02, Vol.25 (1), p.73-82

2018

Volltextzugriff (PDF)

Regional process redesign of lung cancer care: a learning health system pilot project

Current oncology (Toronto), 2018-02, Vol.25 (1), p.59-66

2018

Volltextzugriff (PDF)

A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies

Investigational new drugs, 2020-10, Vol.38 (5), p.1442-1447

2020

Volltextzugriff (PDF)

Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis

Annals of oncology, 2018-10, Vol.29, p.viii106-viii107

2018

Volltextzugriff (PDF)

Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC) in MONALEESA-2

European journal of cancer (1990), 2017-02, Vol.72, p.S1-S2

2017

Volltextzugriff (PDF)

Clinician participation in CADTH's pan-Canadian Oncology Drug Review: contribution and impact on cancer drug funding recommendations

Current oncology (Toronto), 2017-04, Vol.24 (2), p.71-74

2017

Volltextzugriff (PDF)

Treatment patterns and survival in patients with ALK- positive non-small-cell lung cancer: a Canadian retrospective study

Current oncology (Toronto), 2016-12, Vol.23 (6), p.e589-597

2016

Volltextzugriff (PDF)

Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2016-11, Vol.16 (6), p.1106-1112

2016

Volltextzugriff (PDF)

PCN140 The Evaluation of Health Care Resource Utilization in Patients With Metastatic Castration Resistant Prostate Cancer: Results of a Multinational Observational Study

Value in health, 2012-11, Vol.15 (7), p.A435-A435

2012

Volltextzugriff (PDF)

The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit

Annals of oncology, 2010-02, Vol.21 (2), p.232-237

2010

Volltextzugriff (PDF)

Physician "out of office" alert: does it work?

Current oncology (Toronto), 2017-06, Vol.24 (3), p.e176-179

2017

Volltextzugriff (PDF)

PCN116 Mapping FACT-P to EQ-5D in a Large Cross-Sectional Study of Metastatic Castrate-Resistant Prostate Cancer Patients

Value in health, 2012-11, Vol.15 (7), p.A430-A430

2012

Volltextzugriff (PDF)

Estimating Prevalence of Prostate Cancer Clinical States Using a Dynamic Patient Progression Model

Value in health, 2013-11, Vol.16 (7), p.A397-A397

2013

Volltextzugriff (PDF)

1 – 25 von 97

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(96)
Mit Volltextzugriff
(95)

Publikationsform

Artikel
(96)
Berichte
(1)

Sprache

Englisch
(97)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(24)
Science & Technology
(24)
Oncology
(19)
Humans
(13)
Chemotherapy
(9)
Male
(9)
Original
(9)
Aged
(8)
Female
(7)
Lung Cancer
(7)
Middle Aged
(7)
Adult
(5)
Aged, 80 And Over
(5)
Antineoplastic Agents - Therapeutic Use
(5)
Lung Neoplasms - Drug Therapy
(5)
Lung Neoplasms - Pathology
(4)
Non-Small-Cell Lung Cancer
(4)
Patients
(4)
Quality Of Life
(4)
Treatment Outcome
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials

Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients

Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting

Consolidative durvalumab outcomes in stage III non-small cell lung cancer in a multi-centre study

The role of palliative chemotherapy in hospitalized patients

The most important attribute: stakeholder perspectives on what matters most in a physician

Chemotherapy in recurrent advanced non-small-cell lung cancer after adjuvant chemotherapy

Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients?

Palliative chemotherapy in advanced colorectal cancer patients 80 years of age and older

Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 patient-reported outcomes (PROs)

Analyzing the effect of physician assignment in the survival of patients with advanced non-small-cell lung cancer

Non-bacterial thrombotic endocarditis during treatment for EGFR mutation positive lung cancer

Standardizing biomarker testing for Canadian patients with advanced lung cancer

Regional process redesign of lung cancer care: a learning health system pilot project

A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies

Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis

Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC) in MONALEESA-2

Clinician participation in CADTH's pan-Canadian Oncology Drug Review: contribution and impact on cancer drug funding recommendations

Treatment patterns and survival in patients with ALK- positive non-small-cell lung cancer: a Canadian retrospective study

Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3

PCN140 The Evaluation of Health Care Resource Utilization in Patients With Metastatic Castration Resistant Prostate Cancer: Results of a Multinational Observational Study

The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit

Physician "out of office" alert: does it work?

PCN116 Mapping FACT-P to EQ-5D in a Large Cross-Sectional Study of Metastatic Castrate-Resistant Prostate Cancer Patients

Estimating Prevalence of Prostate Cancer Clinical States Using a Dynamic Patient Progression Model

Suchergebnisse filtern